Paydas S - Search Results

1

GC-MS based metabolite fingerprinting of serous ovarian carcinoma and benign ovarian tumor.

Eroglu EC, Kucukgoz Gulec U, Vardar MA, Paydas S. Eroglu EC, et al. Among authors: paydas s. Eur J Mass Spectrom (Chichester). 2022 Feb;28(1-2):12-24. doi: 10.1177/14690667221098520. Epub 2022 May 3. Eur J Mass Spectrom (Chichester). 2022. PMID: 35503418

2

Comparative analysis of CA 125, ferritin, beta-2 microglobulin, lactic dehydrogenase levels in serum and peritoneal fluid in patients with ovarian neoplasia.

Kucukgoz Gulec U, Paydas S, Guzel AB, Buyukkurt S, Seydaoglu G, Vardar MA. Kucukgoz Gulec U, et al. Among authors: paydas s. Med Oncol. 2012 Dec;29(4):2937-43. doi: 10.1007/s12032-012-0165-4. Epub 2012 Jan 25. Med Oncol. 2012. PMID: 22274916

3

Adenosine deaminase activity in patients with ovarian neoplasms.

Urunsak IF, Gulec UK, Paydas S, Seydaoglu G, Guzel AB, Vardar MA. Urunsak IF, et al. Among authors: paydas s. Arch Gynecol Obstet. 2012 Jul;286(1):155-9. doi: 10.1007/s00404-012-2279-5. Epub 2012 Mar 7. Arch Gynecol Obstet. 2012. PMID: 22395862

4

Preoperative evaluation, clinical characteristics, and prognostic factors of nongenital metastatic ovarian tumors: review of 48 patients.

Guzel AB, Gulec UK, Paydas S, Khatib G, Gumurdulu D, Vardar MA, Altintas A. Guzel AB, et al. Among authors: paydas s. Eur J Gynaecol Oncol. 2012;33(5):493-7. Eur J Gynaecol Oncol. 2012. PMID: 23185795

5

Prognostic importance of survivin, Ki-67, and topoisomerase IIα in ovarian carcinoma.

Kucukgoz Gulec U, Gumurdulu D, Guzel AB, Paydas S, Seydaoglu G, Acikalin A, Khatib G, Zeren H, Vardar MA, Altintas A. Kucukgoz Gulec U, et al. Among authors: paydas s. Arch Gynecol Obstet. 2014 Feb;289(2):393-8. doi: 10.1007/s00404-013-3000-z. Epub 2013 Aug 22. Arch Gynecol Obstet. 2014. PMID: 23974278

6

The relationship between ovarian volume and serum CA-125 levels.

Gulec UK, Paydas S, Guzel AB, Vardar MA, Urunsak IF, Cetin MT. Gulec UK, et al. Among authors: paydas s. Eur J Gynaecol Oncol. 2014;35(3):280-3. Eur J Gynaecol Oncol. 2014. PMID: 24984541

7

The clinical characteristics and outcomes of cases with pure ovarian clear cell, mixed type and high-grade serous adenocarcinoma.

Kucukgoz Gulec U, Paydas S, Guzel AB, Vardar MA, Khatib G, Gumurdulu D. Kucukgoz Gulec U, et al. Among authors: paydas s. Arch Gynecol Obstet. 2015 Oct;292(4):923-9. doi: 10.1007/s00404-015-3699-9. Epub 2015 Apr 9. Arch Gynecol Obstet. 2015. PMID: 25855053

8

Primitive uterine neuroectodermal tumours: Two case reports.

Eskiyörük İ, Küçükgöz Güleç Ü, Paydaş S, Güzel AB, Vardar MA, Bağır E. Eskiyörük İ, et al. Among authors: paydas s. Turk J Obstet Gynecol. 2015 Sep;12(3):185-187. doi: 10.4274/tjod.58295. Epub 2015 Sep 15. Turk J Obstet Gynecol. 2015. PMID: 28913066 Free PMC article.

9

Prognostic value of pre-operative neutrophil/lymphocyte ratio, monocyte count, mean platelet volume, and platelet/lymphocyte ratio in endometrial cancer.

Temur I, Kucukgoz Gulec U, Paydas S, Guzel AB, Sucu M, Vardar MA. Temur I, et al. Among authors: paydas s. Eur J Obstet Gynecol Reprod Biol. 2018 Jul;226:25-29. doi: 10.1016/j.ejogrb.2018.05.028. Epub 2018 May 22. Eur J Obstet Gynecol Reprod Biol. 2018. PMID: 29804024

10

Programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) expressions in type 2 endometrial cancer.

Kucukgoz Gulec U, Kilic Bagir E, Paydas S, Guzel AB, Gumurdulu D, Vardar MA. Kucukgoz Gulec U, et al. Among authors: paydas s. Arch Gynecol Obstet. 2019 Aug;300(2):377-382. doi: 10.1007/s00404-019-05180-2. Epub 2019 May 10. Arch Gynecol Obstet. 2019. PMID: 31076855

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

390 results

Search Page